News
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS
Humana Foundation $5.5 Million Investment Sustains Health Equity Momentum in Targeted Communities
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, continued its $5.5 million investment in six communities across the United States to improve greater
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received a Phase II
Dexcom Announces Four-for-One Forward Stock Split
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one
Dexcom Announces Four-for-One Forward Stock Split
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one
LivaNova to Announce First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2022, the period ended February 28, 2022, after the close of the
DGAP-News: Fresenius Medical Care participates in three-way merger to create premier value-based kidney care provider in the U.S. - next important step in execution of growth strategy 2025
DGAP-News: Fresenius Medical Care beteiligt sich an Fusion dreier Partner zum führenden Anbieter wertbasierter Nierentherapie in den USA - nächster wichtiger Schritt zur Umsetzung der Wachstumsstrategie 2025
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the National
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla
Southcoast Behavioral Health Expands Services and Capacity
Southcoast Behavioral Health today reinforced its strong commitment to the communities it serves through the addition of a dedicated child and adolescent behavioral health program, expanding the
Premier Inc. Named One of the 2022 World’s Most Ethical Companies® by Ethisphere® for 15th Consecutive Year
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P
Simulations Plus Releases MembranePlus 3.0
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced it has